Marketable Securities

12 Months Ended

Jun. 30, 2017

Marketable Securities

Marketable Securities

3.     Marketable Securities

Immunomedics considers all of its current investments to be available-for-sale. Marketable securities at June 30, 2017 consist of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized
	Cost		Gain		(Loss)		Fair Value
U.S. Treasury Bonds	$	35,086	$	—	$	(24)	$	35,062
Certificate of Deposits		15,298		—		—		15,298
U.S. Government Sponsored Agencies		18,357		—		(13)		18,344
Corporate Debt Securities		32,692		—		(33)		32,659
Commercial Paper		10,144		1		—		10,145
	$	111,577	$	1	$	(70)	$	111,508

Maturities of debt securities classified as available-for-sale were as follows at June 30, 2017 (in thousands):

			Net Carrying
	Fair Value		Amount
Due within one year	$	89,477	$	89,728
Due after one year through five years		22,031		22,149
	$	111,508	$	111,877

Marketable securities at June 30, 2016 consisted of the following (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized
	Cost		Gain		(Loss)		Fair Value
U.S. Treasury Bonds	$	5,059	$	6	$	—	$	5,065
Certificate of Deposits		3,000		3		—		3,003
U.S. Government Sponsored Agencies		14,311		31		—		14,342
Corporate Debt Securities		15,014		2		(2)		15,014
	$	37,384	$	42	$	(2)	$	37,424